Vedere Bio is a privately held, emerging biopharmaceutical company discovering and developing next generation ocular gene therapies to make vision restoration a reality. Vedere is developing a pipeline of novel vision restoration and preservation therapies that will bring life-changing technology to a global unmet medical need. In 2020 Novartis acquired Vedere Bio Inc., leading to the formation of Vedere Bio II to continue pursuing next generation ocular gene therapies for vision restoration.
| Headquarters | Cambridge, MA |
| Website | www.vederebio.com |
| Pipeline Status | Preclinical |
| @VedereBio | |
| Vedere Bio |